Melanoma Group

Home | Research & Innovation | Scientific Programmes | Molecular Oncology Programme | Melanoma Group

Staff Scientists

  • Nuria Gago
  • David Olmeda

Post-Doctoral Fellows

  • María Magdalena Leal
  • Adriana Sanna

Graduate Students

  • Xavier Catena
  • Marta Contreras
  • Naiara Juan
  • Sergio Oterino
  • Thelma Poluha


  • Tonantzin Guadalupe Calvo
  • Cynthia Mucientes
  • Mireia Vallespinós

Melanomas are the only tumours where lesions barely over one millimetre in depth can be at risk for metastasis. An increasing number of (epi)genetic alterations and mechanisms of immune evasion have been identified in this disease. Nevertheless, no molecular biomarker has been approved as a bona fide prognostic indicator. The field is also in need of improved treatments, as a significant fraction of patients is resistant to targeted and immune-based therapies. The long-term goal of our Group is to identify new progression biomarkers and anticancer agents. We are particularly interested in defining lineage-specific vulnerabilities that distinguish melanomas from other tumours with lower metastatic potential (publications in Nature, Cancer Cell, Nature Cell Biology, Nature Communications, among others). Our laboratory has also generated first-in-class lymphoreporter mice for non-invasive imaging of pre-metastatic niches in melanoma (Nature) and has identified actionable immune suppressive mechanisms with implications for patient treatment (Nature Medicine). Our ultimate objective is to improve the management of patients with otherwise refractory metastatic melanomas.